NASDAQ: AVBP
Arrivent Biopharma Inc Stock Ownership - Who owns Arrivent Biopharma?

Insider buying vs selling

Have Arrivent Biopharma Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Hillhouse Investment Management Ltd10% Owner2025-12-10555,555$23.37
$12.98MSell
Robin LachapelleChief Operating Officer2025-07-112,050$2.28
$4.67kBuy
Robin LachapelleChief Operating Officer2025-07-112,600$2.28
$5.93kBuy
Robin LachapelleChief Operating Officer2025-07-116,503$2.28
$14.83kBuy

1 of 1

AVBP insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when AVBP insiders and whales buy or sell their stock.

AVBP Shareholders

What type of owners hold Arrivent Biopharma Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Infinitum Asset Management LLC8.85%4,123,923$119.68MInstitution
Suvretta Capital Management LLC8.82%4,106,035$119.16MInstitution
Hhlr Advisors Ltd8.44%3,929,117$114.02MInstitution
Hillhouse Investment Management Ltd8.44%3,929,117$114.02MInsider
Fmr LLC7.95%3,703,572$107.48MInstitution
Orbimed Advisors LLC6.50%3,027,328$87.85MInstitution
Blackrock Inc5.09%2,372,838$68.86MInstitution
Octagon Capital Advisors LP4.23%1,971,054$57.20MInstitution
Novo Holdings A4.17%1,942,142$56.36MInstitution
Vanguard Group Inc4.01%1,869,266$54.25MInstitution

1 of 3

AVBP vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
AVBP80.12%19.88%Net Selling
CRVS55.52%38.89%Net Buying
MLTX76.56%22.22%Net SellingNet Selling
GHRS75.07%24.19%
KALV62.24%37.76%Net SellingNet Selling

Arrivent Biopharma Stock Ownership FAQ

Who owns Arrivent Biopharma?

Arrivent Biopharma (NASDAQ: AVBP) is owned by 86.11% institutional shareholders, 21.37% Arrivent Biopharma insiders, and 0.00% retail investors. Hillhouse Investment Management Ltd is the largest individual Arrivent Biopharma shareholder, owning 3.93M shares representing 8.44% of the company. Hillhouse Investment Management Ltd's Arrivent Biopharma shares are currently valued at $113.83M.

If you're new to stock investing, here's how to buy Arrivent Biopharma stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.